Form D · Other Health Care
Synereca Pharmaceuticals, Inc.
Oklahoma City, OK · CIK 0001487939
Offering snapshot reported Aug 15, 2017 · SEC filing
- Reported sold
- $600K Offering amount: $1.2M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 2, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 15, 2017 | Initial | $600,000 | No comparison | 10 | SEC filing |
| Feb 8, 2011 | Initial | $300,492 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-292834
Source: Form D, filed Aug 15, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Corrigan | Director |
| Clayton I. Duncan | Director, Executive |
| Richard E. Gammans | Executive, Promoter |
| Bennett W. Love | Director |
| W Bennett Love | Director, Executive |
| Scott Meacham | Director |
| Richard W Reichow | Executive |
| Scott F. Singleton | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
865 Research Parkway Suite 400
Oklahoma City, OK, 73104
Oklahoma City, OK, 73104